Influenza A virus (IAV) |
NP |
NP enhances p53 stabilization and apoptosis, enhancing virus release from infected cells |
[12,14–15] |
Zika virus (ZIKV) |
ZCP |
ZIKV triggers p53-induced cell death in neural cells and progenitors |
[18,19] |
HIV type 1 (HIV-1) |
Nef Tat Vif |
Nef may inhibit p53 function during early steps of viral replication; Vif may increase p53 function and contribute to cytopathic effects. Inhibition of SIRT1 by tat may modulate p53 acetylation and activation |
[20–22] |
Human herpes simplex virus 1 (HSV-1) |
ICP0 ICP22 ICP27 |
ICP27 is a transcriptional target of p53. ICP0 targets HAUSP and enhances p53 degradation. p53 regulates ICP0 degradation. ICP22 prevents the negative regulation of ICP0 by p53 |
[23,24,25] |
Epstein--Barr virus (EBV) |
BZLF1 EBNA1 EBNA3C LMP1 |
BZLF1 induces Mdm2-independent p53 degradation. EBNA1 prevents p53 and Mdm2 degradation, modulating p53-dependent repair and apoptosis. EBNA3C repress DNA-binding and transcriptional activity. LMP1 promotes p53 accumulation and impair cell-cycle arrest and apoptosis |
[26–28,29] |
High -risk papilloma viruses (HPV 16, 18, 31, 45) |
E6, E7 |
E6 binds E6AP and induces p53 degradation. Disruption of pRb by E7 abrogate p53 downregulation of DREAM |
[30–31,33] |
Hepatitis B virus (HBV) |
HBx |
HBx re-directs and re-wire p53 transcriptional activity. Mutant HBx form an oncogenic complex with mutant TP53 p.R249S |
[35–36] |
SARS-CoV viruses |
Nsp2, nsp3 |
Nsp2 interacts with prohibitin (PHB) 1 and 2, involved mitochondrial biogenesis, causing ROS release and inducing p53 through DNA damage Nsp3 is a multidomain protein that binds and activates RCHY1, inducing Mdm2-independent p53 degradation |
[4,13,46] |